Global Invasive Pneumococcal Disease Market - 2023-2030

Global Invasive Pneumococcal Disease Market - 2023-2030

Global invasive pneumococcal disease market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.

Invasive Pneumococcal Disease (IPD) is a severe and potentially life-threatening infection caused by the bacterium Streptococcus pneumoniae, also known as pneumococcus. This disease occurs when these bacteria invade normally sterile parts of the body, such as the bloodstream, lungs, or brain, leading to conditions like pneumonia, meningitis, and sepsis.

IPD mainly affects vulnerable populations, including young children, the elderly, and people with weakened immune systems. To combat this significant public health concern, several vaccines have been developed, with the most prominent ones being the Pneumococcal Conjugate Vaccines (PCV) and the Pneumococcal Polysaccharide Vaccines (PPSV). These vaccines help prevent pneumococcal infections and have played a vital role in reducing the incidence of invasive pneumococcal disease worldwide, especially among children and at-risk adults.

Market Dynamics: Drivers and Restraints

Increasing vaccination programs by government organizations is expected to drive market growth

Immunization programs led by governments and aimed at increasing vaccine coverage, particularly for children, have been instrumental in driving growth in the field of pneumococcal disease prevention. These programs are designed to reduce the burden of invasive pneumococcal disease and lower healthcare costs associated with its treatment. By prioritizing childhood immunization, governments promote preventive healthcare, thereby reducing the incidence of the disease. This leads to fewer hospitalizations, doctor visits, and antibiotic prescriptions, as well as a healthier and more productive population.

For instance, in September 2023, the Vaccination Subsidy Scheme (VSS) offered subsidized seasonal influenza and pneumococcal vaccinations to eligible Hong Kong residents through private doctors. Doctors who enroll to provide vaccinations to eligible individuals are reimbursed by the government. In addition, they have the option to charge an extra fee on top of the government subsidy. For the 2023-24 season, the Scientific Committee on Vaccine Preventable Diseases, which operates under the Centre for Health Protection, has recommended seasonal influenza and pneumococcal vaccinations to boost the immunity of high-risk individuals.

In addition, the awareness campaigns accompanying these initiatives promote the importance of vaccination, leading to higher vaccination rates and more informed healthcare decisions. In the long run, while these programs require investment, they yield substantial cost savings by averting the economic and healthcare burdens linked to invasive pneumococcal disease, ultimately contributing to the growth of the pneumococcal vaccine market.

Furthermore, the increasing prevalence of pneumococcal infections, public health campaigns, and increased awareness about the severity of the infections. This has led to a higher demand for vaccination and treatment options, and increasing clinical trials of drugs are the other factors expected to drive over the forecast period.

Restraint:

High vaccine costs, supply chain challenges, the emergence of antibiotic-resistant strains of pneumococcus, and competing health priorities are the factors expected to hamper the market over the forecast period.

For more details on this report – Request for Sample

Segment Analysis

The global invasive pneumococcal disease market is segmented based on age group, vaccine type, end-user and region.

The pneumococcal conjugate vaccines (PCV) from the vaccine type segment accounted for approximately 56.4% of the invasive pneumococcal disease market share

Preventing Invasive Pneumococcal Disease (IPD) is crucial, and Pneumococcal Conjugate Vaccines (PCV) play a vital role in achieving that. These vaccines are specifically designed to protect against infections caused by Streptococcus pneumoniae bacteria, which can cause severe illnesses such as meningitis, pneumonia, and sepsis. PCVs are unique because they target specific strains of the bacterium by combining them with a carrier protein. This technique enhances their effectiveness, especially in vulnerable populations like the elderly and children. The benefits of using PCVs are that they can reduce the incidence of pneumococcal disease, hospitalizations, and antibiotic use, ultimately saving lives and reducing healthcare costs.

The PCV market is driven by various factors, such as vaccination programs led by governments, rising awareness about the significance of prevention, an increase in the incidence of diseases, FDA approvals, increasing clinical trials, and continuous research and development efforts aimed at enhancing vaccine effectiveness and extending coverage. These factors work together to support the ongoing growth of the PCV market as it battles invasive pneumococcal disease.

For instance, on July 27, 2023, Merck, also known as MSD outside of the United States and Canada, announced that two Phase 3 trials evaluating their investigational 21-valent pneumococcal conjugate vaccine have produced positive results in both previously vaccinated and vaccine-naïve individuals. If approved, this vaccine would be the first of its kind specifically designed for adults. The STRIDE-3 trial showed that immune responses were significantly higher in vaccine-naïve adults who received V116 compared to PCV20 (pneumococcal 20-valent conjugate vaccine) for serotypes common to both vaccines. This was determined by serotype-specific opsonophagocytic activity (OPA) 30 days after vaccination. Positive immune responses were also observed for serotypes unique to V116.

Additionally, on June 08, 2021, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has given its approval for PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) to be used as a preventive measure against invasive disease and pneumonia-caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes in adults aged 18 years or older. The U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) is expected to update its recommendations on the safe and appropriate use of pneumococcal vaccines in adults after a meeting in October, following the FDA's approval.

Geographical Analysis

North America accounted for approximately 42.4% of the market share in 2022

North America is expected to hold the largest market share, owing to the increasing clinical trials, growing FDA approvals, increasing prevalence of invasive pneumococcal disease, and increasing vaccination coverage among people.

For instance, on April 27, 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved PREVNAR 20(20-valent Pneumococcal Conjugate Vaccine) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcal) serotypes contained in the vaccine in infants and children six weeks through 17 years of age, and for the prevention of otitis media in infants six weeks through five years of age caused by the original seven serotypes contained in PREVNAR.

Likewise, according to the Centers for Disease Control and Prevention Report 2023, states that approximately 30,000 invasive pneumococcal disease (IPD) cases and 3,000 IPD deaths occur among U.S. adults each year. Therefore, there is an increase in the demand for pneumococcal conjugate vaccines (PCV) and pneumococcal polysaccharide vaccines (PPSV) in the region.

COVID-19 Impact Analysis

The COVID-19 pandemic had a significant impact on the invasive pneumococcal disease (IPD) market. Studies have shown a decrease in IPD cases, indicating that measures like lockdowns and social distancing have reduced the transmission of respiratory pathogens, including pneumococcus. For instance, a study conducted in Catalonia, Spain found a significant reduction in IPD cases in children during the COVID-19 pandemic.

However, some studies have shown an increase in IPD cases, suggesting that the pandemic and associated interventions have led to a decline in routine immunization coverage, increasing susceptibility to pneumococcal disease. For example, a study conducted in England found an increase in IPD cases among children after COVID-19 restrictions were lifted.

It is important to note that the impact of COVID-19 on IPD and its vaccines is complex and may vary depending on factors such as vaccination coverage, age, and underlying health conditions. Nevertheless, studies suggest that pneumococcal and COVID-19 vaccinations are crucial in preventing IPD and reducing the risk of dual infection, particularly in vulnerable populations. Healthcare providers should be aware of the added risk of IPD during the COVID-19 pandemic and encourage vaccination to prevent pneumococcal disease.

Market Segmentation:

By Age Group
• Pediatric
• Adult

By Vaccine Type
• Pneumococcal Conjugate Vaccines (PCV)
• Pneumococcal Polysaccharide Vaccines (PPSV)

By End-User
• Hospital & Clinics
• Government Organizations
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the invasive pneumococcal disease market include Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc., Vaxcyte, Serum Institute of India Pvt. Ltd., Panacea Biotec Limited, Shenzhen Kangtai Biological Products Co., Ltd., SK Bioscience, Walvax Biotechnology Co., Ltd., and Pnuvax Incorporated among others.

Key Development
• On March 17, 2022, Shenzhen Kangtai Biological Products Co., Ltd signed a framework agreement with Phil.PharmaWealth Inc., the largest importer of Parenteral Products in the Philippines, and both parties reached an agreement on jointly promoting the registration application and commercial sales of BIOKANGTAI's 23-valent pneumococcal polysaccharide vaccine in the Philippines.
• On May 21, 2022, Yuxi Walvax Biotechnology Co., Ltd., a subsidiary of Walvax Biotechnology Co., Ltd., successfully produced and delivered one million doses of its 13-valent pneumococcal polysaccharide conjugate vaccine (""PCV13"") to the Kingdom of Morocco. The shipment was celebrated in a ceremony held in Yuxi Municipality, Yunnan, China on Saturday, May 21st, 2022.

Why Purchase the Report?
• To visualize the global invasive pneumococcal disease market segmentation based on age group, vaccine type, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of invasive pneumococcal disease market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global invasive pneumococcal disease market report would provide approximately 61 tables, 55 figures, and 189 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies